Literature DB >> 10470842

Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis.

Y Hosoya1, A Gemma, M Seike, F Kurimoto, K Uematsu, S Hibino, A Yoshimura, M Shibuya, S Kudoh.   

Abstract

The PTEN/MMAC1 gene located at 10q23, has been proposed to be a tumor suppressor gene. To determine the involvement of alteration of the PTEN/MMAC1 gene in carcinogenesis and the progression of primary lung cancers, we analyzed tumor samples of primary and distant metastatic sites and normal lung tissue samples of 30 patients with advanced lung cancer with distant metastasis. The tissues were analyzed for allelic deletion and mutational inactivation of PTEN/MMAC1 by loss of heterozygosity (LOH) analysis, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP), and direct sequence analysis. LOH of the PTEN/MMAC1 locus was common in each histologic type of primary lung cancer. In this study, the overall allelic deletion rate was 33.3% (7/21). Allelic loss at the primary site and that at the metastatic site of each patient, were identical; in most cases, it seemed that the allelic loss had occurred before metastasis. Sequence analysis of the PTEN/MMAC1 gene revealed a G to C substitution located 8 bp upstream of the coding region of exon 1 and which seems to be a polymorphism, in 4 of the 30 cases. Somatic mutations of the PTEN/MMAC1 gene were not identified in any of the tumors at the primary and metastatic sites. These data indicate that point mutations in the PTEN/MMAC1 gene are probably not an important factor in tumorigenesis and the progression of a major subset of lung cancers. Due to frequent allelic loss at the PTEN/MMAC1 locus occurring at a stage earlier than the metastatic process, alternative mechanisms in which the remaining allele is inactivated such as methylation or homozygous deletion of a small region of the gene that can not be detected by the usual analysis, or alteration of other important tumor suppressor genes lying close to the PTEN/MMAC1 gene on 10q23, may be involved in the tumorigenesis of lung cancers of all histologic subtypes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470842     DOI: 10.1016/s0169-5002(99)00052-5

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

1.  Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas.

Authors:  Nicola Amodio; Marianna Scrima; Lucia Palaia; Ali Naeem Salman; Alfina Quintiero; Renato Franco; Gerardo Botti; Pino Pirozzi; Gaetano Rocco; Nicla De Rosa; Giuseppe Viglietto
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

Review 2.  Overview upon miR-21 in lung cancer: focus on NSCLC.

Authors:  Cecilia Bica-Pop; Roxana Cojocneanu-Petric; Lorand Magdo; Lajos Raduly; Diana Gulei; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

3.  PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.

Authors:  Lin Yang; Li-Ge Kuang; Hua-Chuan Zheng; Jin-Yi Li; Dong-Ying Wu; Su-Min Zhang; Yan Xin
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

4.  Phosphatases: the new brakes for cancer development?

Authors:  Qingxiu Zhang; Francois X Claret
Journal:  Enzyme Res       Date:  2011-10-31

5.  Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies.

Authors:  Jay W Tichelaar; Yu Zhang; Jean C leRiche; Paul W Biddinger; Stephen Lam; Marshall W Anderson
Journal:  BMC Cancer       Date:  2005-12-06       Impact factor: 4.430

6.  Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

Authors:  Rintaro Noro; Akihiko Gemma; Seiji Kosaihira; Yutaka Kokubo; Mingwei Chen; Masahiro Seike; Kiyoko Kataoka; Kuniko Matsuda; Tetsuya Okano; Yuji Minegishi; Akinobu Yoshimura; Shoji Kudoh
Journal:  BMC Cancer       Date:  2006-12-06       Impact factor: 4.430

7.  Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

Authors:  Y Kokubo; A Gemma; R Noro; M Seike; K Kataoka; K Matsuda; T Okano; Y Minegishi; A Yoshimura; M Shibuya; S Kudoh
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

8.  Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry; Pankaj Taneja
Journal:  Clin Med Insights Oncol       Date:  2013-06-03

Review 9.  Dysregulation of mTOR activity through LKB1 inactivation.

Authors:  Wei Zhou; Adam I Marcus; Paula M Vertino
Journal:  Chin J Cancer       Date:  2013-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.